Group 1 - The company has undergone management adjustments, including the resignation of the former chairman and other board members, to align with new legal requirements and improve governance structure [1][2] - The management changes are seen as proactive adjustments to enhance governance and internal supervision, with experienced personnel being appointed to the board [1][3] - The company is focusing on high-tech pharmaceutical packaging solutions, indicating a strategic shift towards higher value-added products [2][3] Group 2 - The company is currently experiencing a "growing pain" period during its transformation, with a clear strategic focus on high-tech pharmaceutical packaging, which requires significant capital investment [2][3] - Despite short-term financial pressures, the company continues to invest in R&D and talent acquisition to maintain technological leadership and future growth potential [2][3] - Shareholder reductions are explained as normal market behavior, with specific reasons related to fund lifecycle and employee stock plan considerations [3][4] Group 3 - The company is expected to overcome short-term development bottlenecks and enhance profitability and market competitiveness as the market stabilizes and new capacities come online [4]
力诺药包：积极回应市场关切，多维度展现转型决心与战略定力